Carsten Thiel Impacts The World Through Medicine


Throughout his career in biotechnology, Carsten Thiel has always placed a lot of importance on the concept of ethics in medicine and business. He is currently serving EUSA Pharma as its European President.

Over the years, Carsten Thiel has played a part in the launch of important medications and products like Prolia, Neulasta, Strensiq, and more.

Through the work that he has done, Carsten Thiel has improved the lives of patients suffering from different conditions around the globe. Many of the treatments created by the companies that he was working with are considered medical breakthroughs and many of them treat illnesses in which there had previously been no other options.

In the case of one of the treatments spearheaded by Carsten Thiel, the population that it was designed to help were young children who were dealing with a degenerative bone disease known as hypophosphatasia. While the medication could make a huge difference in the lives of the children being treated, it needed to be given by injection.

Many children are very phobic of needles and Carsten Thiel knew that something had to be done to counter this as it was important the injections be delivered several times a week. They used creative solutions such as the “buddy system” to help these children alleviate some of their fears. See This Page for additional information.

Carsten is dedicated to being able to help people through his work and strives to create humane solutions to problems while showing empathy. He is a native of Berlin Germany and has always done well throughout his education.

He attended the University of Bristol where he earned a Bachelor’s of Science in organic chemistry before eventually earning a Molecular Biology Ph.D. from the Max Planck Institute for Biophysical Chemistry. After graduating, he took a position with the biotechnology firm Hoffman la-Roche and has been moving up in the industry ever since.


Like him on




From The Stone Age to Dr. Ira Kirschenbaum A Brief History Orthopedics

Orthopedic surgeon Dr. Ira Kirschenbaum received his medical degree from the Albert Einstein College of Medicine. Chairman of Orthopedic Surgery for the Bronxcare Health System Dr. Kirschenbaum is renowned as a surgeon and medical innovator. Having performed thousands of joint replacement surgeries Dr. Ira Kirschenbaum has designed special instruments for use during unicompartmental knee replacements. He has also developed a method of hip replacement that doesn’t require cement. Dr. Kirschenbaum is also a medical educator and entrepreneur. He created and sold the online medical journal Medscape.

Part Of An Ancient Tradition

When Dr. Ira Kirschenbaum sets broken limbs he is practicing a skill that was developed in the Stone Age. The first known medical text to address orthopedic injuries was written by the Ancient Egyptian physician Imhotep. The writings of Hippocrates discuss fractures and their treatment in depth. The “Father of Sports Medicine” was the Roman Galen of Pergamon who treated gladiators.

The Middle Ages Through the Renaissance

During the Middle Ages advancements in medicine all but ceased. Guy de Chauliac did, however, develop a way of managing femur fractures that Dr. Ira Kirschenbaum and his colleagues still use today. The original Renaissance man Leonardo da Vinci’s contribution to orthopedics was his detailed renderings of human anatomy.

The Birth of Modern Orthopedic Surgery

Facilities devoted specifically to orthopedics began springing up in the late 19th and early 20th century. During the 1960s Sir John Charnley developed the joint replacement surgery that physicians like Dr. Ira Kirschenbaum routinely perform today. Russel Hibbs conceiving a way to fuse bone during spinal surgery moved orthopedics farther forward. The advent of X-rays was a boon to the diagnosis and treatment of orthopedic conditions. As imaging methods ie; CT Scans and MRIs improve orthopedic surgery will improve with them.

Find out more here

Appointment of New Leaders at EUSA Pharma to Strengthen Management Team


EUSA Pharma (EUSA), is a global biopharmaceutical company that focuses on the treatment of oncology and other rare infections. The company was launched in March 2015. With many years of prosperity in delivering world-class products, the company has developed extensive commercial networks in the United States and around Europe, as well as the establishment of direct presence in other selected markets in the world.


EUSA Pharma is managed by a team of focused leaders who have many years of experience as well as recommendable records in developing successful pharmaceutical companies. The company also receives significant financial support from one of the leading life science investor, EW Healthcare Partners.


With the aims of improving the efficiency of service delivery, the company created new positions. It was on 15th May, when the company made the official announcement that it had appointed Dr. Carsten Thiel to fill the position of President in charge of the company’s affair in Europe and Dr. Darrel p. Cohen to take over the new post as the Head of Clinical Development.


Carsten Thiel is a well-known figure in the pharmaceutical and biopharmaceutical professions. Dr. Carsten Thiel, a Ph.D. holder, brings extensive experience of over 27 years gained serving in a variety of international roles in the pharmaceutical industry. Prior to this post, he was serving as the CEO of a US-based company, Abeona Therapeutics, as a gene therapy specialist. He also worked for several years at Alexion Pharmaceutical as the CEO where he led the company’s EMEA, Asia, Pacific, and Australasia organizations.


Carsten Thiel is an authority in biotechnology having spent a good number of years in the industry. He believes that the field has entered its golden age and the future holds a lot of promise. Answers to pertinent human concerns like living disease-free lives are sure to be addressed during this period. See This Page for additional information.


On the other hand, Dr. Darrel P. Cohen is a qualified oncologist specialist with two decades of clinical development experience in the pharmaceutical industry. Before joining EUSA, Dr. Cohen was a Vice President of Pfizer’s International Oncology firm where he led the company with remarkable achievements. He also worked at Duke University in the department of medicine where he served as an Associate Tutor and Oncology Fellow.


View source: